Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.58 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2556203 | 0.83 | TRIM24 (0.53) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL209092 | 0.81 | TRIM24 (0.63) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7977848 | 0.80 | TRIM24 (0.53) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4935664 | 0.80 | TRIM24 (0.62) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4940215 | 0.79 | TRIM24 (0.66) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18871942 | 0.79 | TRIM24 (0.66) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL24411118 | 0.78 | PDE10A (0.46) | KDM4ESMN1; SMN2 | |
| SCHEMBL25141707 | 0.78 | KCNJ1 (0.42) | — | |
| SCHEMBL2561698 | 0.78 | TRIM24 (0.83) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3077544 | 0.78 | TRIM24 (0.83) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029215-A | Amino group-containing acetal-type releasable polyoxyethylene derivative, process for producing the same, and amino group-containing acetal-type releasable polyoxyethylene conjugate | 日油株式会社 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025084230-A1 | ACETAL-TYPE RELEASABLE POLYOXYETHYLENE DERIVATIVE CONTAINING AMINO GROUP, METHOD FOR PRODUCING SAME, AND ACETAL-TYPE RELEASABLE POLYOXYETHYLENE CONJUGATE CONTAINING AMINO GROUP | 日油株式会社 | 2025-04-24 | — | — | WO | disclosed |
| WO-2021231927-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2019199816-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| EP-2928890-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2018-02-28 | — | — | EP | disclosed |
| US-9453013-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-27 | — | — | US | disclosed |
| US-9453013-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-27 | — | — | US | disclosed |
| US-8980913-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-8980913-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-12 | — | — | US | disclosed |
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-12 | — | — | US | disclosed |
| WO-2014086927-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-12 | — | — | WO | disclosed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | TRIM24 2341/4885TRIM33 2795/4885ALDH1A1 1182/4885 |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | HRH2, HNMT, HRH3 | TRIM24 4737/4885TRIM33 3990/4885ALDH1A1 719/4885 |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | HRH2, HNMT, HRH3 | TRIM24 4737/4885TRIM33 3990/4885ALDH1A1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.